Overview
Introduces drug design based on cancer pathophysiology
Describes the benefits of a drug delivery system that integrates nanotechnology, biotechnology, and nano biotechnology
Explains the new cancer drug step by step
Access this book
Tax calculation will be finalised at checkout
Other ways to access
Table of contents (14 chapters)
-
Front Matter
-
Hybrid Techniques of Active and Passive Targeting
-
Front Matter
-
-
Cancer Stromal Targeting (CAST) Therapy and Diagnosis
-
Front Matter
-
-
The Current Status of Cancer Drug Delivery Systems and Future Directions
-
Front Matter
-
Keywords
About this book
This book proposes the importance of new systems of drug design and delivery based on cancer pathophysiology in addition to cancer molecular and cellular biology. The current studies based on molecular and cellular biology while ignoring pathophysiology and pharmacology may be leading the development of antitumor drugs in the wrong direction and wasting a lot of money. Although there have been numerous reports of genetic and phenotypic changes in tumors, a large body of pathological and clinical evidence supports the conclusion that there are no pivotal changes in tumor cells that distinguish them consistently and reliably from normal dividing cells. Unlike using antibiotics against bacterial infection, therefore, anticancer agents (ACAs) need to be delivered selectively to tumor tissues and should be kept there long enough to reproduce the concentrations they reach in the Petri dish, which is a closed space where the cytocidal effects of any anticancer agents (ACAs) including molecular targeting agents are very strong. In the body, however, administered ACAs are cleared with the passage of time. Furthermore, most human cancers possess abundant stroma that hinders the penetration of drugs into the tumor microenvironment. Therefore, to overcome these difficulties, novel drug delivery systems have been designed, such as nanoparticles and ACA conjugated antibodies to stromal components and to cancer cell surface antigens. These advances are described in this book after the first section, which describes core features of the pathophysiology of the cancer microenvironment, on which these new developments are based.
Editors and Affiliations
About the editors
Yasuhiro Matsumura, MD, PhD, Director, Division of Developmental Therapeutics, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, Japan
David Tarin, MD, PhD, FRCPath, Professor of Pathology, UC San Diego Moores Cancer Center, University of California, USA
Bibliographic Information
Book Title: Cancer Drug Delivery Systems Based on the Tumor Microenvironment
Editors: Yasuhiro Matsumura, David Tarin
DOI: https://doi.org/10.1007/978-4-431-56880-3
Publisher: Springer Tokyo
eBook Packages: Biomedical and Life Sciences, Biomedical and Life Sciences (R0)
Copyright Information: Springer Japan KK, part of Springer Nature 2019
Hardcover ISBN: 978-4-431-56878-0Published: 30 January 2020
eBook ISBN: 978-4-431-56880-3Published: 07 January 2020
Edition Number: 1
Number of Pages: XI, 325
Number of Illustrations: 45 b/w illustrations, 73 illustrations in colour
Topics: Pharmaceutical Sciences/Technology, Cancer Research, Nanoscale Science and Technology